Skip to main content
Premium Trial:

Request an Annual Quote

Rarecells Raises $13M in Series A Round to Develop Liquid Biopsy Early Cancer Detection Tests

NEW YORK – Liquid biopsy firm Rarecells said Thursday that it has closed a $5 million financing tranche, bringing its total Series A funding to $13 million. The funds will support the company's launch of a new US lab, which will advance early detection assays for prostate cancer and acute myeloid leukemia.

Individual investors in the financing round were not named.

Headquartered in Paris, Rarecells has developed a proprietary circulating tumor cell isolation platform, called ISET, short for Isolation by SizE of Tumor Cells, which is coupled with downstream analyses for the detection of tumor-associated signals in the blood. According to the company, its testing involves the use of AI algorithms to analyze immunomorphological cellular profiles and altered genome-wide DNA characteristics.

Besides the early detection tests for prostate cancer and AML, the firm's pipeline of products includes a multi-cancer early detection test.

Rarecells said its ISET platform has been used in research on samples from thousands of cancer patients across stages and tumor types thus far.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.